XML 60 R26.htm IDEA: XBRL DOCUMENT v2.4.1.9
INTANGIBLE ASSETS (Tables)
 3 Months Ended
Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of intangible assets

The following table sets forth the gross carrying amount and accumulated amortization of our intangible assets as of March 31, 2015 and December 31, 2014:

 

   March 31, 2015
   Gross Carrying Amount  Accumulated Amortization  Net
Amount		  Weighted- Average Amortization Period (yrs.)
Amortizing intangible assets:                    
OPERA® software patent  $31,951   $(2,995)  $28,956    14.5 
Development costs of corporate website   91,743    (91,743)   —    n/a 
Approved hormone therapy drug candidate patents   439,184    (25,593)   413,591    17.75  
Non-amortizing intangible assets:                   
Hormone therapy drug candidate patents (pending)   691,465    —    691,465    n/a 
Multiple trademarks for vitamins/supplements   124,738    —    124,738    n/a 
Total  $1,379,081   $(120,331)  $1,258,750      

 

   December 31, 2014
   Gross Carrying Amount  Accumulated Amortization  Net
Amount		  Weighted- Average Amortization Period (yrs.)
Amortizing intangible assets:                    
OPERA® software patent  $31,951   $(2,496)  $29,455    14.75 
Development costs of corporate website   91,743    (91,743)   —    n/a 
Approved hormone therapy drug candidate patents   439,184    (19,401)   419,783    18 
Non-amortizing intangible assets:                    
Hormone therapy drug candidate patents (pending)   675,982    —    675,982    n/a 
Multiple trademarks for vitamins/supplements   103,368    —    103,368    n/a 
Total  $1,342,228   $(113,640)  $1,228,588      

 
Schedule of estimated amortization expense

Estimated amortization expense for the next five years is as follows:

 

Year Ending
December 31,		   Estimated
Amortization
  2015 (9 months)     $ 20,074  
  2016     $ 26,765  
  2017     $ 26,765  
  2018     $ 26,765  
  2019     $ 26,765